financetom
Business
financetom
/
Business
/
AutoZone's Fiscal Q1 Net Income Falls, Sales Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AutoZone's Fiscal Q1 Net Income Falls, Sales Rise
Dec 10, 2024 4:46 AM

07:18 AM EST, 12/10/2024 (MT Newswires) -- AutoZone ( AZO ) reported fiscal Q1 net income Tuesday of $32.52 per diluted share, down from $32.55 a year earlier.

Analysts polled by FactSet expected $33.63.

Net sales for the quarter ended Nov. 23 were $4.28 billion, up from $4.19 billion a year earlier.

Analysts surveyed by FactSet expected $4.30 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: FedEx Fiscal Q1 Adjusted EPS, Revenue Decrease; Shares Fall Pre-Bell
Update: FedEx Fiscal Q1 Adjusted EPS, Revenue Decrease; Shares Fall Pre-Bell
Sep 22, 2024
09:04 AM EDT, 09/20/2024 (MT Newswires) -- (Updates with the revised fiscal 2025 adjusted EPS guidance in the sixth paragraph, as well as the latest stock move in the last paragraph and the headline.) FedEx ( FDX ) reported fiscal Q1 adjusted earnings late Thursday of $3.60 per diluted share, down from $4.55 a year earlier. Analysts polled by Capital...
Canadian Retail Sales Rebound in July, Strength Seen Continuing in August, Says Desjardins
Canadian Retail Sales Rebound in July, Strength Seen Continuing in August, Says Desjardins
Sep 22, 2024
09:00 AM EDT, 09/20/2024 (MT Newswires) -- August's headline retail sales rose 0.9% during the month, besting estimates from economists and the flash estimate from Statistics Canada, said Desjardins. The strength in Friday's headline figure was driven by a rebound in motor vehicle sales following a widespread software outage at dealerships in June. That said, excluding autos and gasoline, sales...
US FDA approves Zevra's treatment for rare genetic disease
US FDA approves Zevra's treatment for rare genetic disease
Sep 22, 2024
Sept 20 (Reuters) - The U.S. Food and Drug Administration approved Zevra Therapeutics' ( ZVRA ) drug for a rare and fatal genetic disorder, making it the first treatment to get a nod for the condition, the health regulator said on Friday. The company has been trying for years to bring the drug to market after the U.S. health regulator...
BioSyent to Purchase Tibelia Assets for 2.3 Million Euros
BioSyent to Purchase Tibelia Assets for 2.3 Million Euros
Sep 22, 2024
09:30 AM EDT, 09/20/2024 (MT Newswires) -- BioSyent ( BIOYF ) said a subsidiary, BioSyent Pharma, will acquire some assets so it can supply Tibelia, a tibolone-based hormone replacement therapy drug, to distributors worldwide. Under an agreement with Novalon and Mithra Pharmaceuticals, BioSyent Pharma will pay 2.3 million euros to acquire the intellectual property, global rights, certain licensing, distribution and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved